Home Bratislava Medical Journal 2022 Bratislava Medical Journal Vol.123, No.10, p.705–709, 2022

Journal info


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564


Aims and Scope
Editorial Info
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.123, No.10, p.705–709, 2022

Title: The expression of selected fibrotic factors in COPD and asthma

Abstract: BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) and asthma are associated with chronic inflammation leading to airway obstruction and remodelling. There is little information on possible differences in the TGFB signalling pathway in the pathologies compared to less severe chronic bronchitis without airway obstruction.
AIM: To assess the expression of the selected TGFB signalling pathway-associated genes in the pathologies.
METHOD: RT-PCR was used to quantify the mRNAs in bronchoalveolar cells obtained from the Czech patients with chronic bronchitis (n = 26), COPD (n = 22), asthmatic (n = 14) patients.
RESULTS: There was no difference in the BAL cell expression of TGFB1-3, TGFBR1-2, SMAD2,4,5, and 7 between our patients with COPD and those with chronic bronchitis. The expressions were also similar in the patients with asthma and chronic bronchitis. There was no difference between the patients with asthma and COPD.
CONCLUSION: Although we observed no differences in our patients, other studies should investigate the genes and their possible correlation with advanced airway obstruction and emphysematous changes (Tab. 2, Fig. 3, Ref. 27). Text in PDF www.elis.sk

Keywords: TGFB signalling pathway, COPD, asthma, chronic bronchitis, bronchoalveolar lavage
Published online: 23-Jul-2022
Year: 2022, Volume: 123, Issue: 10 Page From: 705, Page To: 709

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.